MedImmune Expands BioWa Licensing Deal To Boost Anti-Inflammatory Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Collaboration includes Phase I monoclonal antibody targeting interleukin-5 and BioWa’s antibody-enhancing technology.